http://rdf.ncbi.nlm.nih.gov/pubchem/patent/SG-196826-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cef4f341fe4f2caf061611a818576e40 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 |
| filingDate | 2010-01-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_58b4761f3bc6a4a8dcfcbc7fb31cc627 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ce086fea71c3f06f71a452595b85f63 |
| publicationDate | 2014-02-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | SG-196826-A1 |
| titleOfInvention | Combinations comprising methotrexate and dhodh inhibitors |
| abstract | COMBINATIONS COMPRISING METHOTREXATE AND DHODH INHIBITORS5The present invention provides a combination which comprises (a) methotrexate and (b)a non-hepatotoxic DHODH inhibitor of formula(1):wherein:R9'j~_NI(G2HN~G1R3'¢R4I-R20R'10R'is selected from the group consistingofhydrogen atoms, halogen atoms,C14alkyl,Cs-4cycloalkyl,-CF3and -OCF3,15R is selected from the group consisting2ofhydrogen atoms, halogen atoms andC14alkyl groups,R is selected from the group consisting3of-COOR5,-CONHR tetrazolyl,5,-S02NHR and5-CONHS02R groups, wherein R is selected from the group55consistingofa hydrogen atom and linear or branchedC14alkyl groups,20R is selected from the group consisting4ofa hydrogen atom and a C1•4alkyl group,R is selected from the group consisting9ofa hydrogen atom and a phenyl group,G represents a group selected from N and CR wherein R is selected from the16625group consistingofhydrogen atoms, halogen atoms,c,_.alkyl,C3.4cycloalkyl,c,_.alkoxy, -CF3, -OCF3, monocyclic N-containingCs.7heteroaryl, monocyclic N-containingCs-7 heterocyclyl groups and C6•10aryl groups which C6.10aryl groups areoptionally substituted with one or more substituents selected from halogen atomsand C1•4alkyl groups,4950G represents a group selected from:2• a hydrogen atom, a hydroxy group, a halogen atom, aCs-4cycloalkyl group, ac,_54alkoxy group and -NRaRb, whereinRarepresents a C14alkyl group andRbis selected from a group consisting of C1_4alkyl group and C1•4alkoxy-C14alkyl group,orRaandRbtogether with the nitrogen atom to which they are attached form asaturated 6 to 8 membered heterocyclic ring optionally containing one oxygen10atom as an additional heteroatom,1520• a monocyclicorbicyclic 5 to 10 membered heteroaromatic ring containing one ormore nitrogen atoms whichisoptionally substituted by one or more substituentsselected from halogen atoms,c,..alkyl, C1•4alkoxy,C 3•4cycloalkyl, C,.4cycloalkoxy, -CF3,-OCF and3,-CONR7R wherein R and R are independently8,78selected from hydrogen atom, linear or branchedc,..alkyl groups, C3_7cycloalkylgroups, or R and R together with the nitrogen atom to which they are attached78form a groupofformulawherein n is an integer from 0 to3,and25•a phenyl group which is optionally substituted by oneormore substituents30selected from halogen atoms, C1.4alkyl, hydroxyl,C,_4alkoxy,C34cycloalkyl, C3_ 4cycloalkoxy, cyano, -CF -OCF3,3,-CONR7R oxadiazolyl, triazolyl, pyrazolyl and8,imidazolyl groups, which oxadiazolyl, triazolyl, pyrazolyl and imidazolyl groupsare optionally substituted by C1•4alkylorC3•7cycloalkyl groups and wherein R7and R are independently selected from hydrogen atom, linear or branched8c,..alkyl groups, C3 7_cycloalkyl groups,orR and R together with the nitrogen atom78to which they are attached form a group offormula5051wherein n is an integer from 0to3or, when G' represents CR6,G together with R forms a non-aromatic C265_105carbocyclic group or aCs-10aryl group,and the pharmaceutically acceptable salts and N-oxides thereof.51Figure for publication: None |
| priorityDate | 2009-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 41.